Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease
05 Settembre 2017 - 9:54AM
Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”)
announces the grant of patent number 6169734 entitled “Use of
Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte
Immune Response” by the Japanese Patent Office.
This Japanese patent was filed as a divisional application and
follows the grant of the Japanese parent patent which was issued in
April 2016, as previously reported to the ASX.
The claims of this new patent are geared toward the use of
Prima’s lead candidate IMP321 in the treatment of infectious
diseases. IMP321 will be used alone or in combination with an
anti-infectious chemotherapeutic agent or anti-infectious
immunotherapeutic agent to induce an increase in monocyte numbers -
a type of white blood cell - in order to protect against infectious
disease. Most notably, the new patent points to the broader
potential of IMP321 as an immunostimulant and provides patent
protection in Japan for an additional range of possible clinical
indications, beyond cancer.
The patent expiry date is 3 October 2028.
About Prima BioMed
Prima BioMed is listed on the Australian
Securities Exchange and on the NASDAQ in the US. For further
information please visit www.primabiomed.com.au.
For further information please contact:
U.S. Investors:
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com
Grafico Azioni Immutep Limited (NASDAQ:PBMD)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Immutep Limited (NASDAQ:PBMD)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Immutep Limited (NASDAQ): 0 articoli recenti
Più Articoli Notizie